ClinicalTrials.gg
CompletedNCT01902134DAVID-artUpdated Mar 7, 2016Results posted

Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride

A Phase 3 interventional study of Placebo and Tramadol-single dose in Acute Pain, sponsored by Menarini Group. Completed at 37 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-03-07.

Sponsored by Menarini Group · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
641
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Acute Pain with a site in Poland — 1 open to participants now, 1 under way, none of them phase 3. Acute Pain · Poland.

Enrollment
4th of 18
641 · median 158
Started
2013
with 1 other
Phase 3
6 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
3 of 19
Menarini Group

Among the 19 studies in Acute Pain with a site in Poland, this one is the 4th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 1st registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

1 of the 19 studies in Acute Pain with a site in Poland is open now. Recruiting first, the newest first:

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Acute Pain with a site in Poland, or all of them as a file.
02

Study summary

This study aims to evaluate the analgesic efficacy of single and repeated doses of fixed combination of dexketoprofen trometamol (DKP) and tramadol hydrochloride (TRAM) in comparison to the single agents (and placebo for the single dose phase only) Approximately 600 male and female patients presenting moderate to severe pain after an elective primary hip arthroplasty are eligible to be randomised provided that they experience moderate to severe pain on the day after surgery.

Read the detailed description

In this clinical trial patients were randomized to the described 6 treatment arms, where each arm define the treatment to be received in the first single dose phase (lasting 8 hours after the 1st treatment intake) and in the subsequent multiple-dose phase (lasting from the second treatment intake up to the 8 hours after the last intake). Namely:

  • DKP/TRAM followed by DKP/TRAM;
  • DKP followed by DKP;
  • TRAM followed by TRAM;
  • placebo followed by DKP;
  • placebo followed by TRAM;
  • placebo followed by DKP/TRAM;

The analyses of endpoints pertinent to the single dose phase were performed combining all the 3 treatment arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

The analysis of endpoints pertinent to the multiple dose phase were performed combining the treatment arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

03

Conditions studied

  • Acute Pain

Keywords

  • Moderate to severe acute pain
  • Postoperative pain
  • Hip arthroplasty
  • Analgesics
  • Dexketoprofen
  • Tramadol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 18 to 80 years. Females participating in the study must be either of non-, or willing to use a highly effective method.
  • Scheduled to undergo standard primary (first-time) one-sided total hip replacement surgery due to primary osteoarthritis.
  • Patients experiencing pain at rest of at least moderate intensity the day after surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients not suitable for study treatments and rescue medication (RM) or those for whom non-steroidal anti-inflammatory drugs (NSAIDs), opioids, acetyl salicylic acid, pyrazolones or pyrazolidines are .
  • Patients with abnormalities in vital signs, safety laboratory tests and 12-lead at screening.
  • Patients with history of any illness or condition that might pose a risk to the patient or confound the efficacy and safety study results.
  • Patients using and not suitable to withdraw analgesics other than those specified in the protocol.
  • Patients using and not suitable for withdrawing any of the prohibited medication specified in the protocol.
  • Pregnant and breastfeeding women.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
641 participants (actual)

Study arms

  • Experimental
    DKP/TRAM followed by DKP/TRAM

    Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses

    Drug: Dexketoprofen/Tramadol-single dose · Drug: Dexketoprofen/Tramadol-multiple doses

  • Active comparator
    DKP followed by DKP

    Dexketoprofen-single dose followed by Dexketoprofen-multiple doses

    Drug: Dexketoprofen-single dose · Drug: Dexketoprofen-multiple doses

  • Active comparator
    TRAM followed by TRAM

    Tramadol-single dose followed by Tramadol-multiple doses

    Drug: Tramadol-single dose · Drug: Tramadol-multiple doses

  • Other
    Placebo followed by DKP/TRAM

    Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses

    Drug: Placebo · Drug: Dexketoprofen/Tramadol-multiple doses

  • Other
    Placebo followed by DKP

    Placebo single dose followed by Dexketoprofen-multiple doses

    Drug: Placebo · Drug: Dexketoprofen-multiple doses

  • Other
    Placebo followed by TRAM

    Placebo single dose followed by Tramadol-multiple doses

    Drug: Placebo · Drug: Tramadol-multiple doses

Interventions

  • DrugPlacebo

    Placebo single oral dose (first 8 hours)

  • DrugTramadol-single dose

    Tramadol single oral dose (first 8 hours)

  • DrugDexketoprofen-single dose

    Dexketoprofen single oral dose (first 8 hours)

  • DrugDexketoprofen/Tramadol-single dose

    Dexketoprofen/Tramadol oral single dose (first 8 hours)

  • DrugTramadol-multiple doses

    Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)

  • DrugDexketoprofen-multiple doses

    Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)

  • DrugDexketoprofen/Tramadol-multiple doses

    Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)

06

What researchers measure

Primary outcomes

  1. SPID8 (Sum of Pain Intensity Differences Over 8 Hours)

    Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

    Time frame: over 8 hours after the first dose

Secondary outcomes

  1. SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)

    Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

    Time frame: over 48 hours of the multiple-dose phase

  2. Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)

    Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

    Time frame: over 48 hours of the multiple-dose phase

  3. Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)

    Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

    Time frame: over 8 hours after the first dose

07

Results

Posted Apr 1, 2015

Participant flow

Participant flow — Overall Study
MilestoneDKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAM
Started159161160545354
Single-dose phase159161160545354
Multiple-dose phase159160160545352
Completed151150145524645
Not completed81115279
Withdrew: Adverse event312113
Withdrew: Lack of efficacy002001
Withdrew: Physician decision010000
Withdrew: Protocol violation000001
Withdrew: Withdrawal by subject489154
Withdrew: No compliance100000
Withdrew: Other012010

Outcome measures

PrimarySPID8 (Sum of Pain Intensity Differences Over 8 Hours)

Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

Time frame:
over 8 hours after the first dose
Reported as:
Mean · units on a scale
SPID8 (Sum of Pain Intensity Differences Over 8 Hours)
units on a scaleDKP/TRAMDEXKETOPROFENTRAMADOLPLACEBO
SPID8 (Sum of Pain Intensity Differences Over 8 Hours)246.9 ± 156.50208.8 ± 154.69204.6 ± 145.79151.1 ± 158.51
SecondarySPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)

Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

Time frame:
over 48 hours of the multiple-dose phase
Reported as:
Mean · units on a scale
SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)
units on a scaleDKP/TRAMDEXKETOPROFENTRAMADOL
SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)1943.7 ± 1000.511677.5 ± 1070.911765.6 ± 963.49
SecondaryPercentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)

Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

Time frame:
over 48 hours of the multiple-dose phase
Reported as:
Number · percentage of participants
Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)
percentage of participantsDKP/TRAMDEXKETOPROFENTRAMADOL
Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)90.176.682.2
SecondaryPercentage of Responders According to 50% Max TOTPAR (Total Pain Relief)

Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

Time frame:
over 8 hours after the first dose
Reported as:
Number · percentage of participants
Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)
percentage of participantsDKP/TRAMDEXKETOPROFENTRAMADOLPLACEBO
Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)57.956.551.937.9

Adverse events

Collected over Study duration for patients was up to 6 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DKP/TRAM Followed by DKP/TRAM—2/159 (1.3%)15/159 (9.4%)
DKP Followed by DKP—3/161 (1.9%)18/161 (11.2%)
TRAM Followed by TRAM—1/160 (0.6%)24/160 (15%)
Placebo Followed by DKP/TRAM—1/54 (1.9%)9/54 (16.7%)
Placebo Followed by DKP—0/53 (0%)2/53 (3.8%)
Placebo Followed by TRAM—0/54 (0%)5/54 (9.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAM
Soft tissue infectionInfections and infestations0/1590/1610/1601/540/530/54
Heart valve replacementSurgical and medical procedures1/1590/1610/1600/540/530/54
Vascular graftSurgical and medical procedures1/1590/1610/1600/540/530/54
Face oedemaGeneral disorders1/1590/1610/1600/540/530/54
Laryngeal oedemaRespiratory, thoracic and mediastinal disorders1/1590/1610/1600/540/530/54
Cardiac disorderCardiac disorders1/1590/1610/1600/540/530/54
Periorbital oedemaEye disorders1/1590/1610/1600/540/530/54
HaematuriaRenal and urinary disorders1/1590/1610/1600/540/530/54
Bone operationSurgical and medical procedures0/1591/1611/1600/540/530/54
Device dislocationGeneral disorders0/1590/1611/1600/540/530/54
Most frequent other events
Most frequent other events
EventDKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAM
PyrexiaGeneral disorders3/1599/16111/1603/542/534/54
NauseaGastrointestinal disorders2/1594/1619/1601/540/530/54
Anaemia postoperativeInjury, poisoning and procedural complications7/1596/1615/1603/540/530/54
AnaemiaBlood and lymphatic system disorders3/1591/1611/1603/540/531/54

Baseline characteristics

Intention-to-treat (ITT) population (which includes all patients randomized).

Age, Continuous
Age, Continuous(years)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Mean61.3 ± 10.4363.3 ± 9.0161.3 ± 9.6863.9 ± 9.061.0 ± 11.1059.8 ± 11.3061.9 ± 9.96
Sex: Female, Male
Sex: Female, Male(Participants)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Female868680373324346
Male737580172030295
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Asian0230027
White159159157545352634
Region of Enrollment
Region of Enrollment(participants)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Serbia15181455562
Taiwan0230027
Czech Republic910824336
Hungary495754171611204
Spain1010002
Poland108822333
Ukraine15131366356
Lithuania221921651184
Germany1120004
Latvia373336161516153
Weight
Weight(kg)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Mean83.3 ± 15.3781.4 ± 15.6383.5 ± 17.2582.4 ± 15.9181.7 ± 13.7782.1 ± 15.2782.6 ± 15.80
Height
Height(cm)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Mean168.8 ± 8.99167.9 ± 9.14169.1 ± 9.20166.1 ± 8.47168.0 ± 9.49169.9 ± 7.94168.5 ± 9.01
08

Study locations

37 sites
  • Fakultni nemocnice Brno
    Brno, 625 00, Czech Republic
  • Urazova nemocnice v Brne
    Brno, 662 50, Czech Republic
  • Nemocnice Jihlava, p.o.
    Jihlava, 586 33, Czech Republic
  • Oblastni nemocnice Kladno
    Kladno, 272 59, Czech Republic
  • Oblastni nemocnice Mlada Boleslav a.s.
    Mlada Boleslav, 293 50, Czech Republic
  • Klinikum Frankfurt Höchst GmbH
    Frankfurt am Main, 65929, Germany
  • Uzsoki Hospital, Department of Orthopaedics
    Budapest, 1145, Hungary
  • University of Debrecen
    Debrecen, H-4012, Hungary
  • PTE KK Trauma Központ-Balesetsebészeti és Kézsebésze
    Pécs, 7632, Hungary
  • MÁV Kórház és Rendelőintézet, Ortopédiai osztály
    Szolnok, 5000, Hungary
  • Fejér Megyei Szent György Kórház
    Székesfehérvár, 8000, Hungary
  • Liepaja Regional Hospital
    Liepaja, LV-3414, Latvia
  • Riga's 2nd Hospital
    Riga, LV-1004, Latvia
  • Hospital of Traumatology and Orthopaedics
    Riga, LV-1005, Latvia
  • Vidzemes Hospital
    Valmiera, LV-4201, Latvia
  • Kaunas Clinical Hospital
    Kaunas, LT-44320, Lithuania
  • Hospital of Lithuanian University of Health Sciences Kaunas
    Kaunas, LT-50009, Lithuania
  • Klaipedos Universitetine ligonine
    Klaipeda, 92288, Lithuania
  • Respublikine Vilniaus universitetine ligonine
    Vilnius, LT-04130, Lithuania
  • Uniwersytecki Szpital Klioniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • Warminskie Centrum Ortopedyczne
    Elblag, 82-300, Poland
  • Wojewodzki Szpital Specjalistyczny
    Lublin, 20-718, Poland
  • Specjalistyczny Szpital im. E. Szczeklika
    Tarnow, 33-100, Poland
  • Urazowo - Ortopedycznej Wojewodzkiego Szpitala Specjalistycznego we Wrocławiu
    Wroclaw, 51-128, Poland
  • Medical University of Lodz
    Lodz, Łódzkie 91-002, Poland
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
  • Institute for orthopedic Surgery Banjica [Ortopedic Surgery
    Belgrade, 11000, Serbia
  • Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Clinic for Orthopedic Surgery and Trauma Bul. Dr Zorana Djindjica
    Nis, 18000, Serbia
  • Hospital L'Esperança. Parc de Salut Mar.
    Barcelona, 08024, Spain
  • Hospital Universitario Puerta del Mar
    Cadiz, 11009, Spain
  • China Medical University Hospital [Orthopedic]
    Taichung, 404, Taiwan
  • Kuang Tien General Hospital
    Taichung, 433, Taiwan
  • Cherkaska oblasna likarnia
    Cherkasy, 18009, Ukraine
  • Instytut patologii khrebta ta suglobiv im. prof. M.I. Sytenka NAMN Ukraine
    Kharkiv, 61024, Ukraine
  • Kyivska oblasna klinichna likarnia
    Kyiv, 04107, Ukraine
  • Sevastopolska miska likarnia №9
    Sevastopol, 99018, Ukraine
09

References and documents

Publications

  • McQuay HJ, Moore RA, Berta A, Gainutdinovs O, Fulesdi B, Porvaneckas N, Petronis S, Mitkovic M, Bucsi L, Samson L, Zegunis V, Ankin ML, Bertolotti M, Piza-Vallespir B, Cuadripani S, Contini MP, Nizzardo A. Randomized clinical trial of dexketoprofen/tramadol 25 mg/75 mg in moderate-to-severe pain after total hip arthroplasty. Br J Anaesth. 2016 Feb;116(2):269-76. doi: 10.1093/bja/aev457. PubMed 26787797 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2013
First posted
Jul 18, 2013
Start
Apr 2013
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Apr 1, 2015
Last update
Mar 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01902134
Lead sponsor
Menarini Group
Responsible party
Sponsor
First posted
Jul 18, 2013
Start date
Apr 2013
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Apr 1, 2015
Last update
Mar 7, 2016

Study contacts

Andrew Moore, Professor
study chair · Pain Research & Nuffield Department of Anaesthetics - University of Oxford
Henry J McQuay, Professor
study chair · Balliol College Oxford

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion